CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Triple Negative Breast Cancer
Interventions: DRUG: PLD Chemotherapy|DRUG: CDX-1140|DRUG: CDX-301
Sponsor: University of Texas Southwestern Medical Center
Collaborators: Celldex Therapeutics|Gateway for Cancer Research